Wide Open Agriculture Shuts German Plant and Eyes Asia Contract Model to Cut Costs
WOA charts capital-efficient path with German wind-down and four-stage scale-up
Wide Open Agriculture (ASX: WOA) is restructuring the economics of its lupin ingredients platform, winding down its German production facility immediately and shifting to a contract manufacturing model to reduce cash burn and scale more efficiently.
The strategic pivot marks a move away from owner-operated production toward an asset-light approach. WOA is targeting 500–1,000 tonnes per annum (tpa) of initial contract manufacturing capacity, with Asia identified as its preferred production location.
The company has mapped a four-stage scale-up pathway toward large-scale industrial production, to be executed under new Chief Executive Officer Craig Swan. The German facility, secured through the Prolupin acquisition, has already demonstrated commercial-scale production, and the current initiatives are focused on improving unit economics and reducing capital and fixed-overhead burden.
The company describes the objective as “building better economics” to position for a potential pathway to future profitability.
When big ASX news breaks, our subscribers know first
Why WOA is winding down German operations
The German facility, originally secured through the Prolupin acquisition, fulfilled its purpose as a commercial-scale proof of concept. It enabled WOA to demonstrate lupin protein isolate production at volume, validate its proprietary processing technology, secure regulatory approvals including China market access, and establish customer relationships and operational knowledge.
Continued owner-operation, however, no longer fits the company’s strategy. WOA believes latent demand for its lupin protein isolate and co-products will outstrip the facility’s current capability unless significant additional capital is invested. The facility was also not designed for integrated whole-of-lupin processing at the volumes required for cost-effective commercialisation of oil and fibre, while elevated EU energy and operating costs have continued to negatively impact unit economics.
The wind-down mechanics include:
-
Facility idled immediately, with fixed cost reduction delivered progressively from Q3 to Q4 CY2026
-
No material ongoing costs anticipated after December 2026
-
Wind-down expected to be completed by mid-2027
-
Employee team transitioned, lease obligations finalised, and production equipment offered for sale, with proceeds expected to cover associated wind-down costs
-
German subsidiary, Wide Open Agriculture Germany GmbH, to be wound up through a managed liquidation process
Capital previously absorbed by the German operations will be redeployed toward restarting manufacturing as soon as possible via a contract manufacturing partner.
The four-stage scale-up pathway explained
WOA has structured its roadmap across four distinct stages, progressing from cost reduction to potential large-scale industrial production.
| Stage | Focus | Target Capacity | Key Benefit |
|---|---|---|---|
| Stage One | Wind down German operations | — | Reduce cash burn |
| Stage Two | Contract manufacturing | 500–1,000tpa | Improved margins, lower capex, Asia location |
| Stage Three | Co-product commercialisation & whole-seed utilisation | — | Multiple revenue streams |
| Stage Four | Large-scale expansion (forward planning) | 10,000+tpa | Industrial Australian production (PFS underway) |
Stage Two, the company’s immediate priority, centres on the contract manufacturing model, under which production of its lupin ingredients is outsourced to established third-party facilities. Key benefits the company identifies could include:
-
Improved margin profile through higher throughput and lower energy and labour costs
-
Significantly reduced fixed overhead and capital intensity
-
Ability to scale production in line with confirmed demand
-
Leveraging production expertise from specialist companies
-
A faster pathway to commercial-scale volumes
WOA is in discussions with numerous potential production partners across Asia and is evaluating a short list of preferred suppliers to progress toward more formal agreements, with the protection of its intellectual property (IP) a stated priority.
What is whole-of-seed lupin processing (and why it matters)
A central pillar of WOA’s production process is its ability to extract value from the whole lupin seed rather than protein alone. This “whole-of-seed strategy” adds two further product lines, oil and fibre, alongside the existing protein isolate business.
Why does this matter? Processing a single input into multiple saleable products can drive stronger gross margin per tonne of seed processed and broaden the customer base beyond protein buyers.
Stage Three focuses on the commercial launch of these co-products alongside commercial-scale protein production. The two co-products include:
-
Lupin oil, which is rich in oleic acid and bioactives, with applications across cosmetics and specialty food ingredients. Initial small-scale sales have been secured.
-
Lupin fibre, where independent testing has confirmed strong techno-functional properties, including neutral flavour and aroma, smooth mouthfeel, and strong water and oil binding characteristics. Samples have been provided to universities, research bodies and potential commercial partners.
The expected impact of full-seed utilisation includes stronger gross margins, a broader customer base spanning food, beverage and cosmetics sectors, increased strategic interest from potential partners and investors, and improved sustainability credentials.
The company believes that successful execution of Stage Three, combining lower-cost contract manufacturing with multiple revenue streams, could establish the foundation for a pathway to future profitability.
New leadership to drive execution
Incoming CEO Craig Swan, whose appointment was announced on 3 March 2026, commenced on 7 April 2026 and will lead execution of the strategy. Swan brings senior B2B food ingredients leadership experience across Givaudan, Goodman Fielder Ingredients and Nutrasweet, with depth in Asian markets the company considers critical to its growth.
The update also referenced a renewal of the board alongside the CEO appointment.
Craig Swan’s appointment was structured with 7 million performance options tied to product delivery and share price milestones, signalling the Board’s intent to align executive incentives directly with the commercial execution now required to convert WOA’s technology foundations into revenue.
Justin Brown, Chair, Wide Open Agriculture
“WOA has reached an exciting point in its development, with strong foundations now in place, including proprietary technology, regulatory approvals in key markets, and a global distribution network. I look forward to working alongside Craig and the management team to support the execution of the Company’s commercial strategy, with a clear focus on translating these foundations into long term value for shareholders.”
The next major ASX story will hit our subscribers first
The investment case and what comes next
The strategic thesis centres on growing revenue without the fixed-cost burden of owner-operated production. WOA describes the transition to contract manufacturing as the “critical near-term unlock”, with the removal of the German facility’s overhead and production shifted to a lower-cost jurisdiction expected to materially improve unit economics.
WOA’s lupin royalty renegotiation with Curtin University, which replaced a tiered cost structure with a flat 3.5% of net sales, is one of several parallel moves the company has made to reduce its fixed cost floor ahead of the contract manufacturing transition.
Near-term milestones the market may watch include:
-
Contract manufacturing partner selection, which the company intends to update the market on as arrangements are developed
-
Converting the existing customer pipeline into contracted supply agreements
-
Growing revenue across the protein, oil and fibre portfolio
Looking further out, Stage Four remains forward planning only. WOA is conducting a Pre-Feasibility Study (PFS) for a potential 10,000+tpa Australian facility to assess technical and economic viability, positioning the company for early-stage discussions with potential joint venture partners, strategic investors and government co-funding bodies. Any decision to proceed would be subject to further feasibility work, appropriate funding and Board approval, with the near-term focus remaining on Stages One through Three.
With its technology proven at commercial scale, regulatory approvals secured in key markets, and a growing customer pipeline across food, beverage and cosmetics, WOA is pivoting toward what it describes as better economics for future growth.
Don’t Miss the Next Consumer Sector Breakout
Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements hit. Click the “Free Alerts” button at Big News Blast to get started today.